Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study

Doron Aronson, Joseph Verbalis, Matthias Mueller, Henry Krum

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)


Arginine vasopressin (AVP) V2 receptor antagonism is a new approach to the management of hyponatraemia in congestive heart failure (CHF). The aim of this study was to investigate the efficacy and safety of satavaptan, an oral AVP V2-receptor antagonist, in patients with dilutional hyponatraemia.
Original languageEnglish
Pages (from-to)327 - 336
Number of pages10
JournalEuropean Journal of Heart Failure
Issue number3
Publication statusPublished - 2011

Cite this